ÂÜÀòÂÒÂ×

Mark Rosen has extensive experience in the field of chemistry and drug discovery. Mark is currently serving as the Vice President and Head of Chemistry at Nine Square Therapeutics since January 2021. Prior to this, they worked at Verge Genomics as the Head of Chemistry from November 2018 to January 2021.

Mark also has experience at Regulus Therapeutics as the Director of Chemistry from January 2018 to July 2018, and at Akebia Therapeutics as the Director of Chemistry from June 2016 to January 2018.

In 2014, Mark co-founded Aetheria Therapeutics, Inc., a Johnson & Johnson spinout company, where they were responsible for research and early development activities for the lead clinical candidate.

Before Aetheria Therapeutics, Mark worked at Johnson & Johnson, where they held several positions including Principal Scientist, Medicinal Chemistry from January 2009 to June 2013, Senior Scientist, Medicinal Chemistry from October 2005 to January 2009, and Scientist, Medicinal Chemistry from June 2002 to October 2005. During their time at Johnson & Johnson, they played a key role in the planning, management, and prosecution of medicinal chemistry and drug discovery research programs, leading to the discovery and advancement of multiple clinical compounds. Mark also coordinated scientific research activities between chemistry, biology, pharmacology, and early development groups.

Mark Rosen has a Bachelor's Degree in Chemistry from UC San Diego and a Ph.D. in Organic Chemistry from UC Irvine. No specific start or end years are provided for either of their educational experiences.